Increasing Prevalence of Infections in Hospitals Driving HAI Diagnostics Market

The global hospital-acquired infection (HAI) diagnostics market value is expected to rise from $2,657.6 million in 2016 to $4,386.6 million by 2023, exhibiting a CAGR of 7.6% between 2017 and 2023 (forecast period), as per P&S Intelligence, a market research company based in India. The rising prevalence of infections caused in healthcare settings, such as clinics and hospitals, particularly in emerging countries, due to the poor hygiene in these facilities.

Request to Get the Sample Pages at: https://www.psmarketresearch.com/market-analysis/hospital-acquired-infection-diagnostics-market/report-sample

Furthermore, the emergence of technologically advanced and innovative diagnostic product aids, that provide reliable and accurate results with low turnaround time, is also propelling the demand for HAI diagnostic kits. Moreover, several companies are making huge investments in the development of molecular diagnostics. For example, Hoffmann-La Roche AG announced the launch of the cobas Liat PCR system with four assays in April 2017, which includes a 20-minute real-time PCR nucleic acid test for detecting Clostridium difficile.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=hospital-acquired-infection-diagnostics-market

Of these, the reagents & consumables category held the larger share in the market during the last few years. This was because of the surging incidence of several infectious diseases, such as surgical site infections, bloodstream infections, UTIs, and gastrointestinal infections. Geographically, North America dominated the HAI diagnostics market during the last few years, and this trend is predicted to continue in the coming years as well. This is ascribed to the presence of a well-developed healthcare industry and several HAI diagnostic kit producers in the region.

Additionally, the surging prevalence of nosocomial infections is also driving the demand for HAI diagnostic kits in the region. Currently, the major players operating in the HAI diagnostics market, such as Danaher Corporation, AstraZeneca plc, F. Hoffmann-La Roche AG, Bayer AG, Hologic Inc., Daiichi Sankyo Co. Ltd., Johnson & Johnson, and OpGen Inc., are focusing on collaborations in order to strengthen their position in the industry. For example, Abbott Laboratories and Bigfoot Biomedical Inc. entered into an agreement with each other in July 2017 for developing and selling diabetes management systems in North America.

About P&S Intelligence
P&S Intelligence is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world. Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.

Contact:
P&S Intelligence
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@psmarketresearch.com

This release was published on openPR.